Scotiabank initiated coverage on BridgeBio Pharma
$BBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Scotiabank initiated coverage of BridgeBio Pharma with a rating of Sector Outperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/17/2025 | $49.00 | Outperform | Wolfe Research |
| 3/31/2025 | $50.00 | Buy | Redburn Atlantic |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 10/3/2024 | Perform | Oppenheimer | |
| 9/4/2024 | $46.00 | Overweight | Piper Sandler |
| 3/21/2024 | $45.00 | Outperform | Raymond James |
| 1/31/2024 | $37.00 | Market Perform | BMO Capital Markets |
| 12/8/2023 | $58.00 | Overweight | Wells Fargo |